Teladoc

Rapid expansion of telehealth solutions throughout the pandemic now finds major players battling market and competitive headwinds as the space sorts itself ...

I’m very confident in that impact,” he said. “People are waiting and anxious to see what the early adopters are buying, but we haven’t yet hit the bulk of the market in terms of those who are waiting to see the impact that it will have. Gorevic expects BetterHelp to “grow in the upper half of our long-term target range for mental health revenue growth of 30% to 40% per year” while core services are seeing a shift. Saying Teladoc is “less reliant on paid search as a source of new members than in the past,” Gorevic noted customer acquisition cost (CAC) and related strategies figured prominently, and “our push to diversify customer acquisition channels in recent years has left us better positioned to operate within this environment.” On a call with analysts, CEO Jason Gorevic said Teladoc’s BetterHelp mental health service saw “lower-than-expected yield on marketing spend” adding, “We believe the biggest driver of this dynamic is smaller private competitors pursuing what we think are low- or no-return customer acquisition strategies in an attempt to establish market share.” “We’re seeing clients inundated with a number of new smaller point solutions, which has created noise in the marketplace,” he said.

The virtual care giant reported a $6.7 billion loss in the first quarter, driven by a non-cash goodwill impairment charge related to its 2020 Livongo deal.

Earlier this year, Teladoc launched its own chronic care management program, which it said was accelerated by the Livongo deal. The company's Q1 revenue was $565.4 million, a 25% increase from its $453.7 million revenue in the first quarter last year. "We hold ourselves to a high standard, and there's no question we're disappointed with our revised outlook today," CEO Jason Gorevic said during an earnings call.

Cathie Wood Stock Pick Teladoc Sinks 40% After Slashing Forecast · Ark funds bought shares ahead of Wednesday earnings report · Teladoc drags down other stocks in ...

Teladoc reported a loss of $41.58 per share. Analysts were expecting a loss of 60 cents per share.

Analysts were expecting a loss of 60 cents per share. Teladoc reported a loss of $41.58 per share. The jaw-dropping loss came from an impairment charge of over $6.5 billion.

Teladoc reported it will take a charge of $6.6 billion to write down the value of its acquisitions, reflecting the waning market value of its acquisition of ...

The impairment charge does not impact the company's cash or liquidity. - Large - Small

Cathie Wood's Ark Invest suffered another setback after shares in one of its biggest holdings, Teladoc Health Inc, lost nearly half their value on Thursday ...

Advertisement Advertisement

The huge pandemic boom for virtual health company Teladoc appears to be over.

Teladoc Health (TDOC -40.15%) stock is plummeting following the company's recent first-quarter earnings release and conference call.

It's clear that Teladoc is facing some challenges in addition to the tough comparisons to periods when the pandemic was serving as a more powerful growth catalyst. With the company's target for U.S. paid membership holding steady at between 54 million and 56 million, that suggests that its services could be losing pricing power. A big write-down this quarter was largely to be expected. Since then, growth stocks have seen substantial multiple contraction as risk factors including high inflation and looming interest rate hikes have come into focus, and "pandemic stocks" have also generally fallen out of favor with investors. Teladoc reported Q1 earnings after the market closed yesterday. Teladoc Health ( TDOC -40.15%) stock is plummeting following the company's recent first-quarter earnings release and conference call.

Teladoc Health Inc., the digital health provider that's backed by Cathie Wood's ARK Investment Management LLC, cratered after slashing its forecast on cost ...

Teladoc also faces mounting rivalry in the telemedicine space. ARK is Teladoc’s largest shareholder, with a 12% stake that was worth about $1.1 billion as of the close Wednesday, according to Bloomberg data. Teladoc, a former stay-at-home winner, extends a slump that’s wiped out roughly 90% of its value from a record high in February last year.

The news: Teladoc reported that its Q1 year-over-year revenue grew 25% from $453.7 million in 2021 to $565.4 million in 2022. However, Teladoc execs lowered ...

- Livongo missed analysts’ expectations for membership growth in the last two quarters of 2021. But it’s also important to note: While telehealth companies are experiencing a bit of a slump now, telehealth isn’t going anywhere. - For example, telehealth giant Amwell lowered its revenue outlook in Q3’21 and missed analyst expectations for quarterly revenues at the end of 2021. The bigger picture: Teladoc is not alone in its post-COVID growing pains. - Teladoc still expects more top-line revenues to come in from its new chronic care business, Chronic Care Complete, which launched in February. The news: Teladoc reported that its Q1 year-over-year revenue grew 25% from $453.7 million in 2021 to $565.4 million in 2022.

Catherine Wood, chief executive officer of ARK Investment Management LLC, speaks during the Bitcoin 2022 conference in Miami, Florida, U.S., on Thursday, ...

Ford, Amazon wrote-down stakes in Rivian. Google, Microsoft said equity bets lost value. But it's the $6 billion charge from Teladoc that really stands out.

But in an earlier era, it took Amazon a full decade to recover in share price after the dotcom bubble burst. Valuation gains often reflect one element of what makes a bubble: an imbalance between the supply of a particular investment desire and demand, and market bubbles form when too much money is put to work in a particular area that is short on supply. This is why companies like Teladoc had been actively seeking to scale up, and across services, in M&A like the Livongo deal. But Teladoc's CEO also conceded, "it's still sort of on the verge of being finished with the integration, we don't have the proof points behind it. Teladoc bought Livongo for $18.5 billion in cash and stock in late 2020 in the biggest digital health deal to date. "We're seeing clients inundated with a number of new smaller point solutions, which has created noise in the marketplace," Gorevic said. "HR departments are getting squeezed because there's so much going on with respect to return to office, dealing with the Great Resignation and all of the hiring and allocating resources to talent acquisition and retention," Teladoc CEO CEO Jason Gorevic said. Wall Street, which bailed on the stock on Thursday morning, is concerned, with one analyst writing about the "cracks in TDOC's whole health foundation as increased competitive intensity is weighing on growth and margins." There were big winners whose business was directly tied to the risk of pandemic, and whose investors proved the value of their forethought: namely, Moderna Therapeutics. But at a broader stock market level, the digital health trade was in the category of stay-at-home stocks that booked huge gains, as telehealth boomed, with patients required to seek care virtually and as the adoption of digital services across sectors went through years of evolution in a period of months. For any investor who lived through the dotcom bubble and is old enough, or had parents old enough, to be sold on the need to branch out from core equity into sector fund bets on health sciences, telecom and tech funds, the lessons should have been learned long ago. Its 40% dive on Thursday brought into stark relief what's been a yearlong train wreck for the digital health public valuations: competitors AmWell and 1Life Healthcare down more than 80% in the past year, and consumer health care company Him and Hers Health down more than 60%. This week's earnings details have included some big-name reckonings with the value of high-growth, high-tech — and high-risk — companies.

Ark Invest's ace stock picker is catching a falling scalpel, but the prognosis isn't as grim as you think.

Revenue rose 25% for the quarter, weaker than expected -- but still respectable growth in light of the bearish thesis that we would all abandon telehealth and rush back to in-office medical visits. The good news is that Teladoc is still growing. Teladoc announced two summers ago that it would be acquiring Livongo Health for $18.5 billion, and today all of Teladoc is worth less than a third of that initial buyout price. Teladoc posted a huge quarterly loss this week, but the lion's share of that came from a noncash impaired asset charge. Sometimes buying the dip is just a case of snapping turtles all the way down. If Teladoc were back at its highs, the fallen medical tech stock would account for more than a third of all Ark assets.

The Schall Law Firm Encourages Investors in Teladoc Health, Inc. with Losses of $100000 to Contact the Firm.

The Company disclosed a "net loss per share of $41.58, primarily driven by a non-cash goodwill impairment charge of $6.6 billion or $41.11 per share." The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].

Law Offices of Howard G. Smith announces an investigation on behalf of Teladoc Health, Inc. (“Teladoc” or the “Company”) (NYSE: TDOC) investors concer.

On April 27, 2022, Teladoc released its first quarter 2022 financial results, reporting revenue of $565.4 million – $3.23 million less than consensus estimates – and “[n]et loss per share of $41.58, primarily driven by [a] non-cash goodwill impairment charge of $6.6 billion or $41.11 per share.” “[n]et loss per share of $41.58, primarily driven by [a] non-cash goodwill impairment charge of $6.6 billion or $41.11 per share.”Tweet this